

Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/RF9BCF213E0FEN.html>

Date: June 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: RF9BCF213E0FEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Relapsing-remitting multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Relapsing-remitting multiple sclerosis Understanding

Relapsing-remitting multiple sclerosis: Overview

Relapsing-remitting multiple sclerosis (RRMS) - the most common disease course – is characterized by clearly defined attacks of new or increasing neurologic symptoms. These attacks – also called relapses or exacerbations – are followed by periods of partial or complete recovery (remissions). During remissions, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during the periods of remission. RRMS can be further characterized as either active (with relapses and/or evidence of new MRI activity over a specified period of time) or not active, as well as worsening (a confirmed

increase in disability following a relapse) or not worsening. Approximately 85 percent of people with MS are initially diagnosed with RRMS.

'Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsing-remitting multiple sclerosis pipeline landscape is provided which includes the disease overview and Relapsing-remitting multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Relapsing-remitting multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsing-remitting multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Relapsing-remitting multiple sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Relapsing-remitting multiple sclerosis.

Relapsing-remitting multiple sclerosis Emerging Drugs Chapters

This segment of the Relapsing-remitting multiple sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsing-remitting multiple sclerosis Emerging Drugs

Orelabrutinib: InnoCare Pharma

Orelabrutinib is an orally bioavailable small molecule Bruton's tyrosine kinase-inhibitor (agammaglobulinaemia tyrosine kinase inhibitor), developed by InnoCare Pharma. The drug is in phase 2 stage of development for the treatment of Relapsing Remitting

Multiple Sclerosis.

BCD-063: Biocad

Biocad is developing glatiramer acetate, designated BCD 063, for the treatment of Relapsing-remitting Multiple Sclerosis. It is a MHC class II gene modulators and is currently in phase 3 stage of development.

Evobrutinib: Merck

Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton's tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.

Further product details are provided in the report..

Relapsing-remitting multiple sclerosis: Therapeutic Assessment

This segment of the report provides insights about the different Relapsing-remitting multiple sclerosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Relapsing-remitting multiple sclerosis

There are approx. 25+ key companies which are developing the therapies for Relapsing-remitting multiple sclerosis. The companies which have their Relapsing-remitting multiple sclerosis drug candidates in the most advanced stage, i.e. phase III include, Biocad.

Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Relapsing-remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsing-remitting multiple sclerosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsing-remitting multiple sclerosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsing-remitting multiple sclerosis drugs.

Relapsing-remitting multiple sclerosis Report Insights

Relapsing-remitting multiple sclerosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Relapsing-remitting multiple sclerosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Relapsing-remitting multiple sclerosis drugs?

How many Relapsing-remitting multiple sclerosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsing-remitting multiple sclerosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Relapsing-remitting multiple sclerosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Relapsing-remitting multiple sclerosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

InnoCare Pharma

Biocad

Biogen

RedHill Biopharma Limited

Immunic AG

Merck Serono

Anokion SA

Apitope Technology

Neurotec Pharma

Mitsubishi Tanabe Pharma Corporation

TG Therapeutics, Inc.

RemeGen Co., Ltd.

Gilead Sciences

GlaxoSmithKline

GeNeuro SA

InteKrin Therapeutics, Inc.

Clene Nanomedicine

Takeda Pharmaceuticals

Mapi Pharma Ltd.

Key Products

Orelabrutinib

BCD-063

BIIB-019

RHB-104

IMU-838

Evobrutinib

ANK-700

ATX-MS-1467

NT-KO-003

MT-1303

TMP001

Ublituximab

RC18

BCD-132

TENOFOVIR ALAFENAMIDE

Belimumab

GNbAC1

INT131

CNM-Au8

Ixazomib

GA Depot

Contents

Introduction

Executive Summary

Relapsing-remitting multiple sclerosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Relapsing-remitting multiple sclerosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Relapsing-remitting multiple sclerosis companies' collaborations, Licensing,
Acquisition -Deal Value Trends

Relapsing-remitting multiple sclerosis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Evobrutinib: Merck

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

RHB-104: RedHill Biopharma Limited

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Relapsing-remitting multiple sclerosis Key Companies

Relapsing-remitting multiple sclerosis Key Products

Relapsing-remitting multiple sclerosis- Unmet Needs

Relapsing-remitting multiple sclerosis- Market Drivers and Barriers

Relapsing-remitting multiple sclerosis- Future Perspectives and Conclusion

Relapsing-remitting multiple sclerosis Analyst Views

Relapsing-remitting multiple sclerosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Relapsing-remitting multiple sclerosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Relapsing-remitting multiple sclerosis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Relapsing-remitting multiple sclerosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/RF9BCF213E0FEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF9BCF213E0FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970